Cancer Biologics Market to record USD 34.97 Bn growth, Evolving Opportunities with Amgen Inc. and AstraZeneca Plc

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The global cancer biologics market size is expected to grow by USD 34.97 billion between 2021 and 2025, expanding at a CAGR of 8.91% during the forecast period. The market is fragmented with the presence of several players. Amgen Inc., AstraZeneca, Bayer AG, Biocon Ltd., Biogen Inc., Bristol-Myers Squibb Co., Celltrion Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., and Merck and Co., Inc. are identified as some of the dominant players in the market. Download PDF Sample Report

The report segments the global cancer biologics market as follows:

• Monoclonal antibodies - size and forecast 2021-2026
• Vaccines - size and forecast 2021-2026
• Cell and gene therapy - size and forecast 2021-2026
• Others - size and forecast 2021-2026

The market growth in the monoclonal antibodies segment will be significant over the forecast period. Monoclonal antibodies are an important part of targeted therapy or immunotherapy for the treatment of cancer. They block tumor growth by acting on specific targets and prevents cancer progression or carcinogenesis. The growth of the segment is accelerating due to new drug approvals as well as the presence of a large number of monoclonal antibodies in the pipeline for the treatment of cancer. For instance, in February 2019, Herceptin Hylecta combination was approved by the FDA for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Such drug approvals are expected to foster the growth of the segment during the forecast period.

• North America - size and forecast 2021-2026
• Europe - size and forecast 2021-2026
• Asia - size and forecast 2021-2026
• Rest of World (ROW) - size and forecast 2021-2026

North America is the major market for cancer biologics. About 53% of the market growth is expected to originate from this region during the forecast period. The rising incidence of cancer in the US and Canada is one of the key factors driving the regional market. For instance, about 237,000 cases of breast cancer are diagnosed in women and about 2,100 in men each year in the US. Also, it was estimated that about 650 children are diagnosed each year with neuroblastoma in the US. In addition to the rising incidence of cancer, the accelerated approvals for cancer biologics granted by regulatory authorities such as the FDA is propelling the growth of the cancer biologics market in North America.

The market is driven by the rising global incidence of cancer. The rise in risk factors such as genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns have increased the prevalence of various types of cancer worldwide. Cancer can occur in any individual irrespective of age or gender. In the US, 89,500 adolescents and young adults aged between 15 and 39 years were diagnosed with cancer, and 9,270 died of the condition in 2020. Also, in 2020, there were 19.3 million new cancer cases and 10 million cancer-related deaths worldwide. The rising prevalence of melanoma, prostate cancer, kidney cancer, liver cancer, lung cancer, breast cancer, uterine cancer, thyroid cancer, and bladder cancer are mainly contributing to the increased number of new cancer cases worldwide. All these factors are contributing to the growth of the global cancer biologics market.

In addition, the rise in strategic collaborations is anticipated to boost the growth of the cancer biologics market.

• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Biocon Ltd.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Celltrion Co. Ltd.
• Cipla Ltd.
• Dr. Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc
• Johnson and Johnson
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Mylan NV

Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request Sample Report Here

• Colorectal Cancer Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026
• Anaplastic Thyroid Cancer Drugs Market by Product and Geography - Forecast and Analysis 2022-2026

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Monoclonal antibodies - Market size and forecast 2021-2026 
• Exhibit 28: Chart on Monoclonal antibodies - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Monoclonal antibodies - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Monoclonal antibodies - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Monoclonal antibodies - Year-over-year growth 2021-2026 (%)

• 5.4 Vaccines - Market size and forecast 2021-2026
• Exhibit 32: Chart on Vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Vaccines - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Vaccines - Year-over-year growth 2021-2026 (%)

• 5.5 Cell and gene therapy - Market size and forecast 2021-2026 
• Exhibit 36: Chart on Cell and gene therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Cell and gene therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Cell and gene therapy - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Cell and gene therapy - Year-over-year growth 2021-2026 (%)

• 5.6 Others - Market size and forecast 2021-2026
• Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Product 
• Exhibit 44: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Japan - Market size and forecast 2021-2026
• Exhibit 70: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 7.9 Germany - Market size and forecast 2021-2026
• Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.10 China - Market size and forecast 2021-2026
• Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.11 UK - Market size and forecast 2021-2026
• Exhibit 82: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 92: Matrix on vendor position and classification

• 10.3 Amgen Inc. 
• Exhibit 93: Amgen Inc. - Overview
• Exhibit 94: Amgen Inc. - Product / Service
• Exhibit 95: Amgen Inc. - Key offerings

• 10.4 AstraZeneca Plc 
• Exhibit 96: AstraZeneca Plc - Overview
• Exhibit 97: AstraZeneca Plc - Product / Service
• Exhibit 98: AstraZeneca Plc - Key news
• Exhibit 99: AstraZeneca Plc - Key offerings

• 10.5 Bayer AG 
• Exhibit 100: Bayer AG - Overview
• Exhibit 101: Bayer AG - Business segments
• Exhibit 102: Bayer AG - Key offerings
• Exhibit 103: Bayer AG - Segment focus

• 10.6 Biocon Ltd. 
• Exhibit 104: Biocon Ltd. - Overview
• Exhibit 105: Biocon Ltd. - Business segments
• Exhibit 106: Biocon Ltd. - Key offerings
• Exhibit 107: Biocon Ltd. - Segment focus

• 10.7 Biogen Inc. 
• Exhibit 108: Biogen Inc. - Overview
• Exhibit 109: Biogen Inc. - Product / Service
• Exhibit 110: Biogen Inc. - Key offerings

• 10.8 Bristol Myers Squibb Co. 
• Exhibit 111: Bristol Myers Squibb Co. - Overview
• Exhibit 112: Bristol Myers Squibb Co. - Product / Service
• Exhibit 113: Bristol Myers Squibb Co. - Key offerings

• 10.9 Celltrion Co. Ltd. 
• Exhibit 114: Celltrion Co. Ltd. - Overview
• Exhibit 115: Celltrion Co. Ltd. - Key offerings

• 10.10 Eli Lilly and Co. 
• Exhibit 116: Eli Lilly and Co. - Overview
• Exhibit 117: Eli Lilly and Co. - Product / Service
• Exhibit 118: Eli Lilly and Co. - Key offerings

• 10.11 F. Hoffmann La Roche Ltd. 
• Exhibit 119: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 120: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 121: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 122: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 123: F. Hoffmann La Roche Ltd. - Segment focus

• 10.12 Merck and Co. Inc. 
• Exhibit 124: Merck and Co. Inc. - Overview
• Exhibit 125: Merck and Co. Inc. - Business segments
• Exhibit 126: Merck and Co. Inc. - Key news
• Exhibit 127: Merck and Co. Inc. - Key offerings
• Exhibit 128: Merck and Co. Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 129: Inclusions checklist
• Exhibit 130: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 131: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 132: Research methodology
• Exhibit 133: Validation techniques employed for market sizing
• Exhibit 134: Information sources

• 11.5 List of abbreviations 
• Exhibit 135: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio